What is DNAtrix?
DNAtrix is a privately held biotech company pioneering virus-driven immunotherapies to combat cancer. Its core technology utilizes a proprietary adenovirus platform, an engineered version of the common cold virus, designed to selectively target and eliminate cancer cells while preserving healthy tissue. The company's lead candidate, DNX-2401, is poised for a global pivotal Phase 3 clinical study for recurrent glioblastoma. Additionally, DNX-2401 is undergoing Phase 1 evaluation for diffuse intrinsic pontine glioma, having received FDA Fast Track and Rare Pediatric Disease designations. A second candidate, DNX-2440, is in Phase 1 clinical trials for colorectal and other cancers with liver metastasis.
How much funding has DNAtrix raised?
DNAtrix has raised a total of $41.9M across 12 funding rounds:
Other Financing Round
$479K
Other Financing Round
$170K
Other Financing Round
$4.5M
Private Equity
$885K
Multiple Rounds
$2.5M
Grant
$10.8M
Series B
$20M
Grant
$2M
Debt
$350K
Other Financing Round (2008): $479K led by Mercury Fund
Other Financing Round (2010): $170K supported by Mercury Fund
Other Financing Round (2012): $4.5M featuring Mercury Fund
Private Equity (2012): $885K, investors not publicly disclosed
Other Financing Round (2013): $160K with participation from Mercury Fund
Other Financing Round (2013): $840K led by Mercury Fund
Series A (2013): $1.5M, investors not publicly disclosed
Grant (2014): $10.8M featuring Cancer Prevention & Research Institute of Texas
Series B (2014): $20M backed by Morningside Ventures, Mercury Fund, and Targeted Technology Fund
Grant (2016): $2M with participation from U.S. Food & Drug Administration
Debt (2020): $350K led by PPP
Key Investors in DNAtrix
Mercury Fund
Mercury Fund is an early-stage venture capital firm that invests in innovative technology companies. Their focus often includes software, data analytics, and other technology-driven sectors, aiming to support startups with disruptive potential.
Morningside Ventures
Morningside Ventures is a venture capital firm that invests in a diverse range of industries, with a notable interest in life sciences and biotechnology. They typically support companies with strong scientific foundations and significant market potential.
U.S. Food & Drug Administration
The U.S. Food and Drug Administration (FDA) is a federal agency responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices. Their involvement often signifies critical milestones in drug development and clinical trials.
What's next for DNAtrix?
With the recent strategic investment and substantial total funding, DNAtrix is well-positioned to advance its clinical programs, particularly the pivotal Phase 3 trial for DNX-2401. The company's focus on a novel oncolytic virus platform suggests a strategy aimed at addressing unmet needs in difficult-to-treat cancers. Future developments will likely involve further clinical trial progression, potential regulatory submissions, and expansion of its therapeutic pipeline. The company's trajectory indicates a strong emphasis on translating its innovative technology into viable cancer treatments.
See full DNAtrix company page
